Search This Blog

Friday, July 12, 2024

Health-Care Companies Are Sending Your Data to Big Tech

 

  • Largest US insurers, hospitals and labs deployed web trackers
  • Health companies have faced lawsuits concerning data exposures

California-based health system Kaiser Permanente recently alerted millions of people that their private information was inappropriately shared with tech giants, angering patients who weren’t aware of the practice.

A Bloomberg News analysis showed the same kinds of online trackers remain on the websites of the nation’s largest health-care companies, often unknown to their millions of patients.

https://www.bloomberg.com/news/articles/2024-07-11/do-health-care-companies-share-my-data-analysis-finds-they-do

Health Alert for Ineligible Meat and Poultry Products Illegally Imported from Philippines

 The U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) is issuing a public health alert for ready-to-eat meat and poultry products that were illegally imported from the Philippines. The Philippines is a country not eligible to export meat and poultry products to the United States. FSIS is continuing to investigate how these products entered the country.

The following products are subject to the public health alert, regardless of the product date [view labels]:

  • 150-g. can of "Argentina BRAND CORNED BEEF."
  • 175-g. can of "Argentina BRAND CORNED BEEF."
  • 260-g. can of "Argentina BRAND CORNED BEEF."
  • 150-g. can of "PUREFOODS CORNED BEEF."
  • 210-g. can of "PUREFOODS CORNED BEEF."
  • 150-g. can of "CHUNKEE CORNED BEEF."
  • 190-g. can of "CHUNKEE CORNED BEEF."
  • 7.43-oz. jar of "Lady's Choice Chicken Spread."

The products subject to the public health alert do not bear any producing establishment information. These items were shipped to restaurant and retail locations in Connecticut, Delaware, Maryland, New Jersey, New York, North Carolina, Ohio, South Carolina, and Virginia.

The problem was discovered when FSIS was performing routine surveillance activities at a retailer and found meat and poultry products from the Philippines that are not eligible to be exported to the U.S.

There have been no confirmed reports of adverse reactions due to consumption of these products. Anyone concerned about an illness should contact a health care provider.

FSIS is concerned that some product may be in consumers' and restaurants' pantries and on retailers' shelves. Retailers who have purchased the products are urged not to sell them. Consumers and restaurants who have purchased these products are urged not to consume or serve them. Consumers are asked to double bag the product when discarding it to reduce the possibility of animals accessing the product because USDA cannot confirm whether the products were properly heated to control pathogens of concern to domestic livestock and poultry.

Consumers and members of the media with questions about the public health alert can contact John Ducar, Owner, Redsealuxury, LLC, at 646-669-4020 or johnny@redsealux.com.

Consumers with food safety questions can call the toll-free USDA Meat and Poultry Hotline at 888-MPHotline (888-674-6854) or send a question via email to MPHotline@usda.gov. For consumers that need to report a problem with a meat, poultry, or egg product, the online Electronic Consumer Complaint Monitoring System can be accessed 24 hours a day at https://foodcomplaint.fsis.usda.gov/eCCF/.

https://www.fsis.usda.gov/recalls-alerts/fsis-issues-public-health-alert-ineligible-meat-and-poultry-products-illegally

Steward Health Care under federal investigation for fraud and corruption

 CBS News has learned federal authorities in Boston have opened a criminal investigation into Steward Health Care, a company that owns dozens of hospitals nationwide, including nine in Massachusetts, according to two people familiar with the matter. Steward, which is based in Dallas, recently filed for bankruptcy.

Federal prosecutors at the U.S. Attorney's office in Boston are investigating Steward Health Care based on various allegations including fraud and violations of the Foreign Corrupt Practices Act, two people familiar with the matter said. The law prohibits U.S. citizens and entities from engaging in corrupt activities when operating overseas.

In addition to its U.S. properties, Steward was tapped by the government in Malta to run three state-owned hospitals. That deal is now at the center of a criminal corruption probe playing out in the island nation. Neither Steward nor its executives have been charged in connection to the matter in Malta. 

The Department of Justice did not immediately respond to CBS News' request for comment. 

Reached Thursday, a spokesperson for Steward had no comment. 

teward filed for bankruptcy reorganization in May and is exploring plans to sell all of its hospitals. Bids for the Massachusetts facilities, which have remained opened during the bankruptcy, are due on Monday. 

Sen. Edward J. Markey, a Democrat from Massachusetts, issued a statement Thursday calling Steward "just the latest example of corporate greed endangering our health system."

"Steward must be investigated, and I hope the company and the corporate executives who facilitated Steward's actions face consequences that reflect the lives, livelihoods, safety, and security that they stole from communities," he said.

The company has been a focus of a year-and-a-half-long CBS News investigation documenting how private equity and other investor groups have siphoned hundreds of millions of dollars from community hospitals with devastating public health consequences

Records reviewed by CBS News showed Steward hospitals around the country left a trail of unpaid bills, at times risking a shortage of potentially life-saving supplies.

The Department of Health in Massachusetts opened an investigation after a woman died after giving birth at a Steward hospital in Boston last October. A complaint made by healthcare workers at the facility, obtained by CBS News, indicates a medical device that might have saved her life had been repossessed by the manufacturer weeks earlier because Steward owed about $2.5 million in unpaid bills.

Steward has become synonymous with the perils of private equity investment in health care. The company started buying up Massachusetts hospitals in 2010, with hundreds of millions of dollars in backing from private equity giant Cerberus.

Cerberus shed its stake in Steward by January 2021, after making an $800 million profit in a decade, according to a report from Bloomberg. Financial records show Steward has also sold off more than $1 billion of its hospitals' land and buildings since 2016 to Medical Properties Trust, which has made a business of buying up hospital real estate from private equity investors. 

A filing with the Securities and Exchange Commission from 2021 shows Steward's owners also paid themselves millions in dividends. Around the same time, Steward CEO Ralph de la Torre acquired a 190-foot yacht estimated to be worth $40 million. 

"They've taken money away from these hospitals that provide needed care and they're using that money to line their own pockets." Massachusetts Gov. Maura Healey told CBS News in February. "I'm disgusted. It's selfish. It's greed."

The company previously told CBS News that executives always put patients first and said they "deny that any other considerations were placed ahead of that guiding principle." The company spokesperson said Steward "has actively and meaningfully invested" in its hospital system since its formation, including in Massachusetts, where it took over hospitals that were "failing" and "about to close."

"Steward Health Care has done everything in its power to operate successfully in a highly challenging health care environment," de la Torre said in a company statement in May. 

https://www.cbsnews.com/news/steward-health-care-federal-investigation-fraud-corruption-hospitals/

'Don't Try ARBs for Severe COVID, Trial Indicates'

 The angiotensin receptor blocker (ARB) losartan led to hypotension and failed to improve mortality in patients hospitalized for acute COVID-19, according to the randomized, prospective -- and prematurely terminated -- ARBs CORONA II trial.

Among 341 patients in Canada and France hospitalized for acute COVID-19, 39.8% of patients who were prescribed losartan developed serious adverse events (SAEs) versus 27.2% in the usual care group (P=0.01), largely due to hypotension in the losartan arm, James Russell, MD, of the University of British Columbia in Vancouver, and colleagues reported in Clinical Infectious Diseases

Of those prescribed losartan, 30.4% developed new-onset hypotension compared with 15.3% of patients in the usual care group (P<0.001). The findings included both ward and intensive care unit (ICU) patients.

"The increased hypotension risk suggests for the first time serious safety concerns with use of ARBs in patients hospitalized for COVID-19," the authors commented. "ARBs should probably not be added to usual care in such patients."

Russell and colleagues were unable to identify any specific markers associated with risk of hypotension.

"[ARBs] are commonly prescribed for conditions such as high blood pressure, heart disease, kidney disease, and diabetes and many of these patients are admitted to hospital with pneumonia," Russell told MedPage Today. "Doctors need to pay close attention and monitor for signs of low blood pressure and acute kidney injury in patients admitted to hospital on losartan or any other of the angiotensin receptor blockers."

The trial was originally designed to assess 28-day mortality among patients who received losartan, and researchers expected that the drug would prove to be safe and potentially decrease mortality in these patients, they wrote. This hypothesis was based on the fact that SARS-CoV-2 infection leads to increased angiotensin II via downregulation of angiotensin-converting enzyme 2, resulting in lung and cardiovascular inflammation and injury.

However, in April 2023, the REMAP-CAPopens in a new tab or window trial found that patients hospitalized for acute COVID-19 who were prescribed ARBs or angiotensin-converting enzyme (ACE) inhibitors had increased mortality and acute kidney injury rates. Consequently, leaders of the ARBs CORONA II trial stopped the trial early and then conducted an unplanned interim analysis when results indicated poorer outcomes with losartan.

Of note, at the time the trial was stopped, there was no significant difference in the original primary outcome of 28-day mortality between the losartan group (6.5%) and the usual care group (5.9%; OR 1.11, 95% CI 0.47-2.64, P =0.81).

However, patients with hypotensive SAEs had over five times the mortality rate compared with those without hypotension in both the losartan (OR 5.37, 95% CI 1.73-16.6) and the usual care arms (OR 6.8, 95% CI 2.00-23.15).

Use of ARBs or ACE inhibitors in patients with COVID-19 remains controversial. Three recent studiesopens in a new tab or window showed no benefit of renin angiotensin system inhibitors in managing COVID-19. And, one recent systematic review and meta-analysisopens in a new tab or window found that initiation of renin angiotensin system blockers increases mortality in patients with severe or critical COVID-19. However, another reviewopens in a new tab or window found that among hospitalized patients with COVID-19, ACE inhibitors or ARBs were not associated with increased mortality risk, ICU admission, or mechanical ventilation.

The National Institutes of Health COVID-19 treatment guidelinesopens in a new tab or window currently recommend that patients with COVID-19 who are receiving ARBs or ACE inhibitors should not stop taking the drugs unless discontinuation is otherwise warranted by their clinical condition.

The ARBs CORONA II prospective, open-label, randomized trialopens in a new tab or window enrolled adults hospitalized with acute COVID-19 between October 2020 and March 2022. Exclusion criteria included acute kidney injury, hyperkalemia, hypotension, use of ARBs or ACE inhibitors within a week of presentation, pregnancy or breast feeding, among others.

Of 341 patients, 171 received losartan and 170 received usual care. Patients in the losartan group received oral losartan 25 to 100 mg/day within 72 hours of hospitalization, which was uptitrated according to treatment tolerance. Treatment with losartan or usual care continued for up to 3 months if a patient was still hospitalized. Of patients in the losartan arm, 65% were treated with 100 mg/day, the maximum dose. About 20% of patients discontinued losartan for SAEs.

The study authors also acknowledged several limitations. In addition to the trial being stopped for safety concerns, there was no placebo group. Also, mortality was lower than expected and may have been due to changes in the virulence of SARS-CoV-2 variants or to newer interventions. Losartan doses may have not been optimal and other ARBs may have proven more effective in reducing mortality, the authors noted.

Disclosures

The study was funded by the Canadian Institutes of Health Research.

Russell reported owning several medical patents related to sepsis and is a shareholder in Molecular You Corp. Other study authors reported no conflicts of interest.

Primary Source

Clinical Infectious Diseases

Source Reference: opens in a new tab or windowTran KC, et al "Effects of losartan on patients hospitalized for acute coronavirus disease 2019: a randomized controlled trial" Clin Infect Dis 2024: DOI: 10.1093/cid/ciae306.

https://www.medpagetoday.com/infectiousdisease/covid19/111069

Inflation Reduction Act made renewables inflation worse

 Who would have predicted that after all the Inflation Reduction Act subsidies, the U.S. would not by now have topped the renewables construction peak, which was achieved under the Trump administration?

Although there have been many assertions that the act’s tax incentives would accelerate renewables and make projects cheaper, that has not occurred. Instead, wind and solar are now much more expensive. As a result, while utility-scale solar construction has expanded, utility-scale wind construction has dropped significantly in the U.S. The year 2020 is still the high watermark for combined solar and wind construction. 

There are several reasons why wind and solar renewables deployment rates have dropped. First, the equipment and construction are substantially more expensive. Wind turbine costs are up over 38 percent since 2021, and total construction costs for wind are up 30 percent from pre-pandemic levels. 

Also, renewables developers have said that, after the passage of the Inflation Reduction Act, many equipment manufacturers simply increased their prices by the amount of the act’s incentive. So the Inflation Reduction Act actually increased inflation for renewables.

The second driver is the higher cost of capital, caused by significantly higher interest rates. Investment grade-rated debt financing rates went from approximately 3 percent to 6 percent, hurting project debt costs for renewables, and the cost of equity for projects went from around 8 percent to 11 percent, according to a June report from CIBC Capital Markets. This led to an almost doubling of the cost of the capital needed for construction projects. 

After the construction inflation and capital cost increases, renewable power prices to consumers have materially increased as well, even after Inflation Reduction Act tax benefits. According to S&P Global, average onshore wind and solar new power sales prices roughly doubled for consumers, going from around $27 per megawatt hour in 2020 to around $55 in 2023.

As a result, while solar construction rates increased, wind construction rates have plummeted more than solar growth. 

Annual new wind installations hit a high in 2020 at 16.1 gigawatts and subsequently fell each year, with only 6.4 gigawatts installed in 2023, a 58 percent drop and the lowest construction rate since 2014. In addition, while onshore wind turbines for the U.S. are mostly made in the U.S., Japan or the European Union, solar mostly comes from China. So the country increased its reliance on Chinese equipment and hurt American manufacturing.

The current administration tried to accelerate renewables construction by borrowing more money and giving it out to renewables projects. Instead, it has caused reduced construction, renewables inflation and increased capital costs, while also increasing the deficit.  

Energy technology innovation, driving down costs leading to energy price deflation and letting the private sector provide low-cost capital has proven to be the best policy for all types of energy, including renewables. 

As Milton Friedman said, “One of the great mistakes is to judge policies and programs by their intentions rather than their results.” This is an apt observation when it comes to current renewables policy and data. 

Paul M. Dabbar was the undersecretary of Energy for Science from 2017 to 2021.

https://thehill.com/opinion/energy-environment/4763935-inflation-reduction-act-renewables/

"Equipment Shutting Down": Union Targets Samsung's AI Chip Plants

 The artificial intelligence boom faces a new challenge this week: The largest union of Samsung Electronics declared an indefinite strike on Monday. By late week, Bloomberg reported the union shifted strike efforts to a critical AI memory plant. 

Let's begin on Monday when the National Samsung Electronics Union announced an indefinite three-day strike, accusing management at the world's largest memory chip manufacturer of being unwilling to negotiate a new labor contract. 

"Management has no intention of dialogue. We have clearly identified line production disruptions and the company will regret this decision," the union wrote in a statement, adding, "Management will eventually relent and come to the negotiating table."

Bloomberg reports that thousands of unionized workers took part in the three-day walkout earlier this week. The company stated, "Samsung Electronics will ensure no disruptions occur in the production lines," noting that it "remains committed to engaging in good faith negotiations with the union." 

By Friday, Bloomberg provided an update on the union's labor action strategy, which appears to have shifted and targeted a high-bandwidth memory production in Pyeongtaek, South Korea. This is the site of the company's most advanced AI memory chip plant. 

Several hundred employees joined protests Thursday and Friday in front of Samsung's high-bandwidth memory site in Pyeongtaek, south of Seoul, after the union called a general strike this week. -BBG

Even though several hundred is far less than several thousand, union leaders told the media outlet that they're now targeting the AI memory chip plant with strikes in hopes of bringing management to the table in a new labor deal. 

More from Bloomberg explaining the importance of the Pyeongtaek plant:

The Pyeongtaek site is the nerve center for Samsung's efforts to carve out a slice of an important market. The chipmaker's in the process of trying to convince Nvidia Corp. to use its high-bandwidth memory — a prerequisite for it to catch smaller rival SK Hynix Inc. in the booming AI arena.

Lee Hyun-kuk, deputy secretary-general of the union, said targeting high-end chip production lines is "the most effective" way to bring management to the negotiating table. 

We noted earlier that Samsung assured no chip production following the labor action by the union. However, on Thursday, the head of the union, Son Woo-mok, told Bloomberg TV that he was hearing significant disruptions at factories. 

"The company is saying that there is no production disruption, but that's not true," Son said, adding, "I'm hearing that there's a lot of equipment that's shutting down, but they don't have the manpower to handle it. So there's a lot of equipment that's going idle."

https://www.zerohedge.com/technology/equipment-shutting-down-union-targets-samsungs-ai-chip-plant

"1st Amendment Is Out Of Control": Academic And Media Figures Rally Against Free Speech

 by Jonathan Turley via jonathanturley.org,

“The First Amendment Is Out of Control.” That headline in a recent column in the New York Times warned Americans of a menace lurking around them and threatening their livelihoods and very lives. That menace is free speech and the media and academia are ramping up attacks on a right that once defined us as a people.

In my new book “The Indispensable Right: Free Speech in an Age of Rage,” I discuss how we are living in the most dangerous anti-free speech period in our history. An alliance of the government, corporations, academia, and media have assembled to create an unprecedented system of censorship, blacklisting, and speech regulation. This movement is expanding and accelerating in its effort to curtail the right that Supreme Court Justice Louis Brandeis once called “indispensable” to our constitutional system.

It is, of course, no easy task to convince a free people to give up a core part of identity and liberty. You have to make them afraid. Very afraid.

The current anti-free speech movement in the United States has its origins in higher education, where faculty have long argued that free speech is harmful. Starting in secondary schools, we have raised a generation of speech phobics who believe that opposing views are triggering and dangerous.

Anti-free speech books have been heralded in the media. University of Michigan Law Professor and MSNBC legal analyst Barbara McQuade has written how dangerous free speech is for the nation. Her book, “Attack from Within,” describes how free speech is what she calls the “Achilles Heel” of America, portraying this right not as the value that defines this nation but the threat that lurks within it.

McQuade and many on the left are working to convince people that “disinformation” is a threat to them and that free speech is the vehicle that makes them vulnerable.

It is a clarion’s call that has been pushed by President Joe Biden who claims that companies refusing to censor citizens are “killing people.” The Biden administration has sought to use disinformation to justify an unprecedented system of censorship.

As I have laid out in testimony before Congress, Jen Easterly, who heads the Cybersecurity and Infrastructure Security Agency, extended her agency’s mandate over “critical infrastructure” to include “our cognitive infrastructure.” The resulting censorship efforts included combating “malinformation” – described as information “based on fact, but used out of context to mislead, harm, or manipulate.” So, you can cite true facts but still be censored for misleading others.

The media has been running an unrelenting line of anti-free speech columns. Recently, the New York Times ran a column by former Biden official and Columbia University law professor Tim Wu describing how the First Amendment was “out of control” in protecting too much speech.

Wu insists that the First Amendment is now “beginning to threaten many of the essential jobs of the state, such as protecting national security and the safety and privacy of its citizens.” He bizarrely claims that the First Amendment “now mostly protects corporate interests.”

So free speech not only threatens your life, your job, and your privacy, but serves corporate masters. Ready to sign your rights away?

Wait, there is more.

There is a movement afoot to rewrite the First Amendment through an amendment. George Washington University Law School Professor Mary Anne Franks believes that the First Amendment is “aggressively individualistic” and needs to be rewritten to “redo” the work of the Framers.

Her new amendment suggestion replaces the clear statement in favor of a convoluted, ambiguous statement of free speech that will be “subject to responsibility for abuses.” It then adds that “all conflicts of such rights shall be resolved in accordance with the principle of equality and dignity of all persons.”

Franks has also dismissed objections to the censorship on social media and insisted that “the Internet model of free speech is little more than cacophony, where the loudest, most provocative, or most unlikeable voice dominates . . . If we want to protect free speech, we should not only resist the attempt to remake college campuses in the image of the Internet but consider the benefits of remaking the Internet in the image of the university.”

Franks is certainly correct that those “unlikeable voices” are rarely heard in academia today. As discussed in my book, faculties have largely purged conservative, Republican, libertarian, and dissenting professors. The discussion on most campuses now runs from the left to far left without that pesky “cacophony” of opposing viewpoints.

Experts at leading universities were fired or stripped of positions for questioning COVID claims. Conservative faculty have been hounded from schools and conservative sites have been targeted by government-funded programs. Thousands have been banned from social media.

What is particularly maddening for many in the free speech community is how the left has responded to opposition to censorship and blacklisting. Some are claiming to be victims by those who criticize their work to target individuals and groups as disinformation.

Others, like comedian Jon Stewart mock those who object to the erosion of free speech by noting that conservatives are making these objections on television or online. So, according to Stewart, how can there be a problem if you are able to still object? The suggestion is that there can be no threat to free speech unless people are completely silenced.

Stewart insists that “we are surrounded by and inundated with more speech than has ever existed in the history of communication.” In other words, because people can still speak, the well-documented systems of censorship and blacklisting must not be so bad.

It is not clear what Stewart would accept as sufficient censorship. In universities, polls show both faculty and students afraid to speak openly. The government has funded a host of programs to pressure the source of revenue of conservative sites and to target dissenting voices. Yet, because we are raising objections to these trends, Stewart laughs at the very notion that free speech is under fire. After all, he is doing just fine.

What appears to be a punchline to Stewart is a bit more serious for others who have their livelihoods threatened by the anti-free speech movement.

Stewart has the benefit of being a liberal comedian on a liberal network. Try being a conservative comedian today getting air time on most cable outlets or college campuses. Like so many academics, everything seems just fine to them. With the purging of opposition viewpoints, those who remain have little to complain about.

The effort to assure citizens that “there is nothing to see here” is belied by a massive censorship system described by one federal court as “Orwellian.” Conservatives face cancel campaigns and blacklisting in academic and media forums.

As I discussed in my new book, conservative North Carolina professor Dr. Mike Adams faced calls for termination for years with investigations and cancel campaigns. He repeatedly had to go to court to defend his right to continue to teach. He was then again targeted after an inflammatory tweet. He was done. Under pressure from the university, he agreed to resign with a settlement. Four years ago this month, Adams went home just days before his final day as a professor. He then committed suicide.

Many others have resigned or retired. For them, the anti-speech movement takes away everything that brings meaning to an intellectual life from publications to associations to even employment. It is a chilling message to others not to join the “cacophony of … unlikeable voices.”

Some citizens seem sufficiently afraid or angry to surrender their free speech rights. They have lost faith in free speech. For the rest of us, their crisis of faith cannot be allowed to become a contagion. We must have a reawakening in this country that, despite our many divisions, we remain united by this indispensable human right.

https://www.zerohedge.com/political/first-amendment-out-control-academic-and-media-figures-rally-against-free-speech